The Pharmacological Landscape of Sickle Cell Disease

• This course closed on December 31, 2025.

Release Date: 8/19/2024 Expiration Date: 12/31/2025 This recording was up to date as of as the release date 8/19/2024 however Pfizer has voluntarily withdrawn Oxbryta from the market as of 9/26/24. Activity Overview The Pharmacological Landscape of Sickle Cell Disease Target Audience This activity is designed for an audience of nurses, nurse practitioners, pharmacists, physician associates, physicians, and social workers. Learning Objectives Upon completion of the educational activity, participants should be able to:

• Describe the pathophysiology of sickle cell disease.
• Differentiate between available FDA approved treatments for sickle cell disease.
• Utilize strategies and resources to support patients navigating treatment for sickle cell disease.

Criteria for Success To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate.  You must participate in the entire activity to receive credit. If you have questions about this activity, please contact AKH Inc. at wendi@akhcme.com. CE credit provided by AKH Inc., Advancing Knowledge in Healthcare. In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and CCOPharma LLC.  AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Associate AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 8/19/2025. PAs should only claim credit commensurate with the extent of their participation. Nurse Practitioners This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and CCOPharma LLC.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1 contact hour(s) (which includes 1 hour(s) of pharmacology). Social Workers As a Jointly Accredited Organization, AKH Inc., Advancing Knowledge in Healthcare is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. AKH Inc. Advancing Knowledge in Healthcare maintains responsibility for this course. Social workers completing this course receive 1 continuing education credit. Commercial Support There is no commercial support for this activity.

Disclosures It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose. Disclosure of Unlabeled Use and Investigational Product  This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer  This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with “Opt Out” in the subject line.

Course Information

Categories: Sickle Cell Disease

Tags: AANP continuing education, AAPA continuing education, AMA continuing education, ANCC continuing education, ASWB continuing education, Nurse continuing education courses, Pharmacist continuing education course, Physician assistant continuing education course, Physician continuing education course, Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disease continuing education, Sickle cell disease treatment, Social work continuing education course, The Pharmacological Landscape of Sickle Cell Disease

Course Instructor

CCOPharma Health Education Author